Multi-target modulation including immune system regulation and tumor microenvironment modification

The phrase "Multi-target modulation including immune system regulation and tumor microenvironment modification" does **not** refer to a single canonical molecule or receptor. Instead, it describes a therapeutic strategy that aims to influence multiple components of both the **immune system** and the **tumor microenvironment**. This approach recognizes that cancer progression and resistance to therapy are driven by complex interactions between malignant cells, various types of immune cells (such as dendritic cells, regulatory T-cells [Tregs], myeloid-derived suppressor cells [MDSCs], macrophages), stromal elements like cancer-associated fibroblasts (CAFs), secreted factors such as cytokines/chemokines/metabolites, and extracellular matrix components[1][3]. Therapies under this umbrella may target: - Immune checkpoints such as PD‑1/PD‑L1. - Immunosuppressive enzymes like indoleamine 2,3-dioxygenase 1. - Pro-tumoral macrophage polarization states. They may also aim to reprogram suppressive elements in the tumor milieu to restore effective anti-tumor immunity[1][4]. Because this term refers broadly to *multiple* targets rather than one defined molecular entity—and encompasses both cellular populations and soluble mediators—it cannot be mapped directly onto standard drug target fields such as "receptor," "enzyme," etc. In summary: This entry does not correspond to a unique molecular target but instead describes an area of therapeutic intervention involving numerous targets within two interconnected biological systems—the immune response network and the tumor-supporting environment. For structured data purposes requiring specificity at the level of individual molecules/receptors/genes/proteins/etc., more precise information would be needed.